IBT
CLDX icon

International Biotechnology Trust’s Celldex Therapeutics CLDX Stock Holding History

International Biotechnology Trust’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$1.32M Hold
48,099
– – 0.45% 44
2023
Q2 		$1.63M Buy
+48,099
New +$1.62M 0.5% 40

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

International Biotechnology Trust's CLDX Position: Q3 2023 in Review

International Biotechnology Trust held its Celldex Therapeutics (CLDX) position steady in Q3 2023 at 48,099 shares worth $1.32M. The position accounts for 0.45% of the portfolio, ranked #44.

International Biotechnology Trust first reported a position in CLDX in Q2 2023 and has held it in 2 quarters since. The position peaked at $1.63M in Q2 2023. 144 funds tracked by Wall St. Rank hold CLDX as of Q3 2023.

  • International Biotechnology Trust held 48,099 shares of Celldex Therapeutics worth $1.32M as of Q3 2023.
  • International Biotechnology Trust left its Celldex Therapeutics share count unchanged in Q3 2023.
  • Celldex Therapeutics made up 0.45% of International Biotechnology Trust's portfolio in Q3 2023, its #44 holding.
  • International Biotechnology Trust first reported a position in Celldex Therapeutics in Q2 2023 and has held it in 2 quarters since.
  • International Biotechnology Trust's Celldex Therapeutics position peaked at $1.63M in Q2 2023.
  • 144 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2023.

Based on International Biotechnology Trust's 13F filing for Q3 2023, filed 14 Nov 2023.